<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103298</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000409754</org_study_id>
    <secondary_id>NCI-05-C-0025</secondary_id>
    <nct_id>NCT00103298</nct_id>
    <nct_alias>NCT00096889</nct_alias>
  </id_info>
  <brief_title>Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and&#xD;
      fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      and giving the drugs in different ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan&#xD;
      followed by combination chemotherapy works in treating patients with unresectable liver&#xD;
      metastases from colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response and duration of response in patients with previously untreated&#xD;
           unresectable liver metastases secondary to colorectal cancer treated with isolated&#xD;
           hepatic perfusion with melphalan followed by leucovorin calcium, oxaliplatin, and&#xD;
           fluorouracil.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the patterns of recurrence (liver vs systemic) in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine progression-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate health-related quality of life with length of survival of patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo exploratory laparotomy. Patients with evidence of carcinomatosis&#xD;
      not previously visualized on scans but found on surgical exploration are removed from the&#xD;
      study. All other patients then undergo isolated hepatic perfusion (IHP). Once IHP is&#xD;
      established, melphalan is administered intra-arterially over 3-5 minutes and then circulated&#xD;
      throughout the liver for 1 hour. Approximately 6-12 weeks later, patients receive systemic&#xD;
      chemotherapy comprising oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2&#xD;
      hours and fluorouracil IV continuously over 22 hours on days 1-2. Courses with systemic&#xD;
      chemotherapy repeat every 14 days for up to 1 year in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, after laparotomy, after completion of systemic&#xD;
      chemotherapy, and then every 6 months thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every&#xD;
      3-4 months for 2 years, and then every 6 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response and duration of response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of health-related quality of life with length of survival</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer&#xD;
&#xD;
               -  Metastatic disease limited to the parenchyma of the liver&#xD;
&#xD;
                    -  No evidence of unresectable extrahepatic disease by preoperative radiology&#xD;
&#xD;
                         -  Limited extra-hepatic disease and dominant life-limiting liver disease&#xD;
                            allowed provided extra-hepatic sites are treatable by local ablative&#xD;
                            measures (e.g., surgical resection or external beam radiotherapy)&#xD;
&#xD;
          -  At least 40% hepatic replacement by tumor by axial CT scan or MRI&#xD;
&#xD;
          -  Unresectable liver metastases, defined by 1 of the following:&#xD;
&#xD;
               -  More than 3 sites of disease in the liver&#xD;
&#xD;
               -  Bilobar disease&#xD;
&#xD;
               -  Tumor abutting major vascular or ductal structures&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hematocrit &gt; 27.0%&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  PT &lt; 2 seconds above upper limit of normal&#xD;
&#xD;
          -  Elevated transaminase levels allowed if due to liver metastases&#xD;
&#xD;
          -  No cirrhosis by biopsy&#xD;
&#xD;
          -  No significant portal hypertension as manifested by any of the following:&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Esophageal varices by endoscopy&#xD;
&#xD;
               -  Significant collateral vessels around the organs drained by the portal venous&#xD;
                  system by radiography&#xD;
&#xD;
          -  No chronic active hepatitis&#xD;
&#xD;
               -  Hepatitis B and C surface antigen negative&#xD;
&#xD;
          -  No history of veno-occlusive disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No ischemic cardiac disease&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  LVEF &gt; 40% by echocardiogram or stress thallium scan (for patients with cardiac&#xD;
             disease)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease or other chronic pulmonary disease&#xD;
&#xD;
          -  Pulmonary function tests ≥ 50% of predicted (for patients with pulmonary disease)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight &gt; 30 kg&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy (including leucovorin calcium, oxaliplatin, and&#xD;
             fluorouracil) allowed provided it was administered &gt; 6 months before liver metastases&#xD;
             were diagnosed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy for this malignancy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent chronic anticoagulation therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Richard Alexander, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

